Celltrion’s Humira Biosimilar Receives U.S. FDA Interchangeability Designation for all Its Approved Dosages and Strengths
The U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for Yuflyma (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and 80mg) presentations. With this approval, Yuflyma is now fully interchangeable with the reference product, Humira (adalimumab), across all marketed dosage forms and strengths. Yuflyma is a high-concentration, citrate-free biosimilar to Humira, approved […]